Pegylated Filgrastim vs. Filgrastim for Stem Cell Mobilization in Multiple Myeloma after Novel Agent Induction

The current standard of care for transplant-eligible myeloma patients is novel agent-based induction followed by high-dose chemotherapy and autologous stem cell rescue. Chemo-mobilization of peripheral blood CD34+ stem cells (PBSC) with pegylated filgrastim (pegfilgrastim), a sustained-duration formulation of filgrastim, has been used as an alternative to filgrastim in several studies involving heterogeneous cohorts of lymphoma and multiple myeloma (MM) patients and shown to be equivalent in PBSC yield and cost-effectiveness.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Publication date: Available online 3 April 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sabina Chiaretti, Elias Jabbour, Dieter Hoelzer The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, allo-SCT should be pursued as soon as possible,...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL. Clin Lymphoma Myeloma Leuk. 2018 Apr 03;: Authors: Chiaretti S, Jabbour E, Hoelzer D Abstract The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Inde...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
Publication date: Available online 3 April 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sabina Chiaretti, Elias Jabbour, Dieter Hoelzer The outcome of adult Acute Lymphoblastic Leukemia (ALL) has substantially improved by adopting pediatric inspired regimens, and about half of the patients are nowadays cured. The evaluation of Minimal Residual Disease (MRD) currently represents the most important prognostic which drive treatment algorithm and which includes allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, Stem Cell Transplantation (allo-SCT) should be pursued as ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion The present study has demonstrated that a single dose of pegfilgrastim is comparable to filgrastim in terms of the timing and efficacy of PBSC harvest and could potentially spare the patient 6 days of filgrastim injections. In addition, ours is the first study to compare these growth factors using vinorelbine/cyclophosphamide as mobilization chemotherapy. Micro-Abstract The current standard of care for transplant-eligible multiple myeloma (MM) patients is novel agent-based (NA) induction followed by high-dose chemotherapy and autologous stem cell transplant (ASCT). This study analyzed the efficacy of pegfilgrast...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Even in the era of novel agents, t(4;14) remains a negative prognostic marker. Frontline autologous stem cell transplant remains as an essential tool when treating these high-risk patients, but further prospective randomized studies are needed to determine the most effective strategy for this patient group. Micro-Abstract This retrospective study analyzed the long-term outcome of 75 patients with t(4;14) multiple myeloma treated in a single center with frontline bortezomib-based treatment. Frontline autologous stem cell transplant following bortezomib-based induction was associated with better progression-free s...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Survival of acute leukemia patients who experience relapse after allogeneic HSCT is poor, especially in elderly patients and those who do not experience remission after relapse treatment. Micro-Abstract In a study of 43 patients to assess the risk factors influencing relapse outcome after hematopoietic stem-cell transplantation in acute leukemia, older age and failure to experience complete remission (CR) after treatment were associated with inferior overall survival. Female sex, extramedullary relapse, and absence of postrelapse graft-versus-host disease (GVHD) were associated with lower CR; and absence of extr...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our results are encouraging and justify evaluation of TECAM versus BEAM (carmustine, etoposide, cytarabine, melphalan) in a prospective multicenter study in a large homogenous patient population. Micro-Abstract High-dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed lymphoma. We retrospectively analyzed the data from 212 lymphoma patients who had undergone ASCT with the TECAM conditioning regimen. The 3-year overall survival, progression-free survival, and death resulting from treatment were comparable to those reported with other conditioning regimens....
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 8 February 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Jill A. Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. Faller High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). However, this treatment regimen is not appropriate for elderly and/or comorbid patients; in these cases, azacitidine is a standard treatment. This systematic review was conducted to ev...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Low EFS and OS rates were found for AML patients in the AYA group. To improve survival rates, intensified chemotherapy regimens and early hematopoietic stem cell transplantation are needed. Micro-Abstract Hispanic patients aged < 40 years with a diagnosis of acute myeloid leukemia (AML) during 2003 to 2016 in Northeast Mexico were evaluated. The group included 46 children and 88 adolescents and young adults (AYAs) aged 15 to 39 years. A greater overall response rate was found in the children (87.2% vs. 69% in AYAs). Low event-free and overall survival rates for AYA patients with AML were documented.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: February 2018 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 2 Author(s): Andrea Tendas, Francesco Marchesi, Ombretta Annibali, Debora Saltarelli, Pasquale Niscola, Alessio Pio Perrotti, William Arcese
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Filgrastim | Hematology | Leukemia | Lymphoma | Myeloma | Neulasta | Neupogen | Stem Cell Therapy | Stem Cells | Study | Transplants